MULTIFACTOR ANALYSIS OF THE ONCOPROTEINS EXPRESSION DEPENDENCE IN GASTRIC CANCER

Authors:

Abstract:

The total of 26 patients operated on for gastric cancer in the period of 2007-2011 was included in the study performed on the basis of the Abdominal Oncology Surgery Department at the CHPI “Odessa Regional Oncologic Dispensary”. In all cases, the so-called lymph node dissections were carried out based on principle considerations, i.e. extensive prophylactic biopsies of visually unchanged lymph nodes. A multifactor analysis of p53, VEGFR-3, Her2/new oncoproteins expression and Ki67 proliferative tumor activity dependence on the involvement of the tumor microcirculatory bed (ly, v), local growth (T), the presence of residual tumor tissue (R), the degree of tumor differentiation (G), the degree of regional lymph nodes involvement (N), the microinfiltration type (Inf α, β, Inf) was performed.

Keywords:

gastric cancer immunohistochemistry oncoproteins

References:

1. Amato M, Perrone G, Righi D. HER2 Status in Gastric Cancer: Comparison between Primary and Distant Metastatic Disease. Pathol Oncol Res. 2016; 30: 1–7.
2. Ananiev J., Gulubova M., ManolovaI., Tchernev G. (2011). Prognostic significance of HER2/neu expression in gastric cancer. Article (PDF Available) in Wiener klinische Wochenschrift 123(13-14):450–4.
3. Chen T, Xu XY, Zhou PH. Emerging molecular classifications and therapeutic implications for gastric cancer. Chin J Cancer. 2016 May 27; 35(1):49. doi: 10.1186/s40880-016-0111-5. Review. PMID:27233623.
4. Gravalos C.; Jimeno A. (2008) HER2 in Gastric Cancer: A New Prognostic Factor and a Novel Therapeutic Target. Ann Oncol. 19(9):1523-1529 (полнотекстовая).
5. Huang G, Chen S, Wang D, Wang R, Lin L, Chen S, Wang L, Huang Q. High Ki67 Expression has Prognostic Value in Surgically-Resected T3 Gastric Adenocarcinoma. Clin Lab. 2016; 62(1-2):141–53.
6. Jørgensen J. T., Hersom M. (2012) HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature. J Cancer 3:137–144. doi:10.7150/jca.4090 (полнотекстовая).
7. Kanayama K, Imai H, Yoneda M, Hirokawa YS, Shiraishi T. Significant intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: A comparative study of immunohistochemistry, FISH, and dual-color in situ hybridization. Cancer Sci. Apr. 2016; 107(4):536–42. doi: 10.1111/cas.12886. Epub 2016 Feb 19.
8. Nadauld L.D., Ford J.M.. (2013) Molecular profiling of gastric cancer: toward personalized cancer medicine. J Clin Oncol. 31(7):838–839. doi: 10.1200/JCO. 2012.47.1714.
9. Rüschoff J. (2012) HER2 testing in gastric cancer: a practical approach. Modern Pathology 25, 637–650.
10. Sheffield BS, Garratt J, Kalloger SE, Li-Chang HH, Torlakovic EE, Gilks CB, Schaeffer DF. HER2/neu testing in gastric cancer by immunohistochemistry: assessment of interlaboratory variation. Arch Pathol Lab Med. 2014; 138(11):1495–502. doi: 10.5858/arpa.2013-0604-OA.
11. Stahl P, Seeschaaf C, Lebok P, Kutup A, Bockhorn M, Izbicki JR, et al. Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer. BMC Gastroenterol. 2015; 15:7.

Publication:

«World of Medicine and Biology» Vol. 17 No. 75 (2021) , с. 79-84
УДК 616.33 - 006.6 - 089.197.5

DOI:

https://doi.org/10.26724/2079-8334-2021-1-75-79-84